Glenmark Pharmaceuticals Experiences Significant Underperformance Amid Mixed Moving Averages
Glenmark Pharmaceuticals Ltd. experienced a decline on January 15, 2025, underperforming its sector. The stock reached an intraday low and showed mixed performance relative to various moving averages. Over the past month, it recorded a decrease, contrasting with the broader market's trends.
Glenmark Pharmaceuticals Ltd. has shown notable activity today, experiencing a decline of 3.4% on January 15, 2025, which is a significant underperformance compared to its sector, lagging by 2.04%. The stock reached an intraday low of Rs 1463.75, marking a decrease of 3.21% during the trading session.In terms of moving averages, Glenmark's stock is currently positioned above the 200-day moving average, while it falls below the 5-day, 20-day, 50-day, and 100-day moving averages, indicating a mixed performance across various time frames.
Over the past month, Glenmark Pharmaceuticals has recorded a decrease of 3.92%, contrasting with the Sensex's decline of 6.63%. On the same day, while the Sensex showed a slight recovery of 0.24%, Glenmark's performance of -3.75% underscores a notable divergence from broader market trends.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Glenmark Pharmaceuticals Sees Notable Surge in Derivatives Open Interest Amid Rising Market Momentum
Glenmark Pharmaceuticals Sees Notable Surge in Derivatives Open Interest Amid Rising Market Activity
Glenmark Pharmaceuticals Sees Notable Surge in Derivatives Open Interest Amid Rising Market Momentum
Most Read
